Source-grounded facts extracted from SpyGlass Pharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SpyGlass Pharma, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2025.
“On March 26, 2026, SpyGlass Pharma, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025.”
SpyGlass Pharma, Inc.: Adopted amended and restated bylaws effective as of the same date (effective 2026-02-09).
“Effective as of February 9, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the completion of the IPO.”
SpyGlass Pharma, Inc.: Filed amended and restated certificate of incorporation in connection with IPO completion (effective 2026-02-09).
“On February 9, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the completion of the IPO.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.